Telbivudine interactions
Full monograph for TelbivudineCheck it against another medicine
Medicines
177 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Interferon Alfa-2a [Recombinant] | Major | Synergy | The risk and severity of peripheral neuropathy may be increased during coadministration of telbivudine with alfa interferons. The mechanism of interaction has… | 5 sources — open the full entry |
| Peginterferon alfa-2a [Pegylated Interferon alfa-2a] | Major | Synergy | The risk and severity of peripheral neuropathy may be increased during coadministration of telbivudine with alfa interferons. The mechanism of interaction has… | 5 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Adalimumab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Adefovir Dipivoxil | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Amikacin | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Amphotericin B | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of…2 documented mechanisms | 1 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Betamethasone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone + Calcipotriol | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Excretion · Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if…2 documented mechanisms | 3 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Excretion · Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if…2 documented mechanisms | 3 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone Dipropionate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone Sodium Phosphate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Betamethasone Valerate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Bromfenac Sodium | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Bumetanide | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Excretion · Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if…2 documented mechanisms | 3 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Excretion · Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if…2 documented mechanisms | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Cisplatin | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatin | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Clotrimazole + Hydrocortisone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
| Colchicine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Colistimethate Sodium | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Crizotinib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Dapsone | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Deferasirox | Moderate | Excretion | Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 1 sources — open the full entry |
| Dexamethasone | Moderate | Synergy | Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if… | 2 sources — open the full entry |
Conditions
Conditions in which Telbivudine needs care, as documented in this source.
Muscular Diseases
MajorProlonged use of certain nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and telbivudine may commonly cause myopathy, including rare cases of rhabdomyolysis. The myopathy may be dose-related and is characterized by persistent, unexplained muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values. Therapy with these NRTIs should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect. Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. NRTI therapy should be interrupted if drug-related myopathy is suspected, and discontinued if myopathy is diagnosed.
2 sources
- "Product Information. Retrovir (zidovudine)." Glaxo Wellcome (2001):
- "Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation (2006):
Diseases requiring hemodialysis
ModerateTelbivudine is removed by hemodialysis. Up to four hours of hemodialysis can reduce systemic telbivudine exposure by approximately 23%. Telbivudine should be administered after hemodialysis. Following dose interval adjustment for creatinine clearance, no additional dose modification is necessary during routine hemodialysis.
1 source
- "Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation (2006):
Kidney Diseases
ModerateTelbivudine is primarily eliminated by the kidney. Compared to patients with normal renal function (CrCl above 80 mL/min), systemic exposure (AUC) of single-dose telbivudine increased by 26% in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min) and 136% in patients with end-stage renal disease managed on hemodialysis. Renal clearance decreased by 66% and 91%, respectively, in patients with moderate and severe renal dysfunction (CrCl below 30 mL/min). Adjustment of the dosing interval is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer's product labeling.
1 source
- "Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation (2006):